 CAMBRIDGE, Mass., Aug. 31, 2021 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. NASDAQ:NTLA, a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPRCas9 technology both in vivo and ex vivo, will present at the following virtual healthcare investor conferences in September: 